Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Micek

Showing results (21-30 of 165) with videos related to

Pageof 17
Sort By:
Current Opinion in Critical Care|May 10, 2026
Antibiotic use in serious infectionsLauren Kolodziej, Sarah S Matuszak, Scott T Micek
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2019
Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically IllMarin H Kollef, Paul Juang, Scott T Micek
Seminars in Respiratory and Critical Care Medicine|February 16, 2022
Antibiotic Optimization in the Intensive Care UnitBryan D Lizza, Nick Raush, Scott T Micek
Infectious Disease Clinics of North America|August 12, 2009
The management of severe sepsis and septic shockMatthew R Morrell, Scott T Micek, Marin H Kollef
Clinical Therapeutics|October 4, 2005
A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemiaAlexandria Garavaglia Wilson, Scott T Micek, David J Ritchie
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|November 17, 2022
Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumoniaMatthew C Bittmann, Scott T Micek, Marin H Kollef
Medicine|October 29, 2011
Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcomeScott T Micek, Richard M Reichley, Marin H Kollef
Pharmacotherapy|November 19, 2003
Management of severe sepsis: integration of multiple pharmacologic interventionsScott T Micek, Rina A Shah, Marin H Kollef
Critical Care Medicine|July 4, 2008
Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implicationsAndrew F Shorr, Scott T Micek, Marin H Kollef
Critical Care Medicine|May 27, 2010
Antimicrobial resistance: consideration as an adverse drug eventSteven J Martin, Scott T Micek, G Christopher Wood
Pageof 17

Showing results (21-30 of 165) with videos related to

Sort By:
Pageof 17
Current Opinion in Critical Care|May 10, 2026
Antibiotic use in serious infectionsLauren Kolodziej, Sarah S Matuszak, Scott T Micek
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2019
Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically IllMarin H Kollef, Paul Juang, Scott T Micek
Seminars in Respiratory and Critical Care Medicine|February 16, 2022
Antibiotic Optimization in the Intensive Care UnitBryan D Lizza, Nick Raush, Scott T Micek
Infectious Disease Clinics of North America|August 12, 2009
The management of severe sepsis and septic shockMatthew R Morrell, Scott T Micek, Marin H Kollef
Clinical Therapeutics|October 4, 2005
A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemiaAlexandria Garavaglia Wilson, Scott T Micek, David J Ritchie
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|November 17, 2022
Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumoniaMatthew C Bittmann, Scott T Micek, Marin H Kollef
Medicine|October 29, 2011
Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcomeScott T Micek, Richard M Reichley, Marin H Kollef
Pharmacotherapy|November 19, 2003
Management of severe sepsis: integration of multiple pharmacologic interventionsScott T Micek, Rina A Shah, Marin H Kollef
Critical Care Medicine|July 4, 2008
Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implicationsAndrew F Shorr, Scott T Micek, Marin H Kollef
Critical Care Medicine|May 27, 2010
Antimicrobial resistance: consideration as an adverse drug eventSteven J Martin, Scott T Micek, G Christopher Wood
Pageof 17